ConductScience.org, home

Paper34278191

Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.

Li Z and 11 others. Res Pract Thromb Haemost, 2021. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors. Papers, record 34278191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34278191

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.
PubMed
Journal
Res Pract Thromb Haemost
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
1.39
iCite
Revised in PubMed
2024-04-02
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li ZZekunhttps://orcid.org/0000-0002-1421-4590
2Chen ZZhenpinghttps://orcid.org/0000-0002-5273-145X
3Liu GGuoqing
4Cheng XXiaoling
5Yao WWanru
6Huang KKunhttps://orcid.org/0000-0003-1641-1472
7Li GGang
8Zhen YYingzi
9Wu XXinyi
10Cai SSiyu
11Poon MCMan-Chiu
12Wu RRunhuihttps://orcid.org/0000-0003-4030-209X

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131447396Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time.Transfus Apher Sci2019https://conductscience.org/library/papers/31447396PubMed
231033112The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.Haemophilia2019https://conductscience.org/library/papers/31033112PubMed
310529689Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome.Vox Sang1999https://conductscience.org/library/papers/10529689PubMed
422101900The principal results of the International Immune Tolerance Study: a randomized dose comparison.Blood2012https://conductscience.org/library/papers/22101900PubMed
517593277International workshop on immune tolerance induction: consensus recommendations.Haemophilia2007https://conductscience.org/library/papers/17593277PubMed
628574205First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.Haemophilia2017https://conductscience.org/library/papers/28574205PubMed
731624794Low-dose immune tolerance induction for children with hemophilia A with poor-risk high-titer inhibitors: A pilot study in China.Res Pract Thromb Haemost2019https://conductscience.org/library/papers/31624794PubMed
823278996Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?Haemophilia2013https://conductscience.org/library/papers/23278996PubMed
923510123Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study.Haemophilia2013https://conductscience.org/library/papers/23510123PubMed
1023157203Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Br J Haematol2013https://conductscience.org/library/papers/23157203PubMed
1120536988Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.Haemophilia2010https://conductscience.org/library/papers/20536988PubMed
1226632988Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors.Thromb Haemost2016https://conductscience.org/library/papers/26632988PubMed
1316409170Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.Haemophilia2006https://conductscience.org/library/papers/16409170PubMed
1428641362Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.Haemophilia2017https://conductscience.org/library/papers/28641362PubMed
1528920105The impact of von Willebrand factor on factor VIII memory immune responses.Blood Adv2017https://conductscience.org/library/papers/28920105PubMed
1631343592Low-dose Immune Tolerance Induction in Hemophilia: A Single-Center Experience.J Pediatr Hematol Oncol2019https://conductscience.org/library/papers/31343592PubMed
1720573153Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches.Br J Haematol2010https://conductscience.org/library/papers/20573153PubMed
1832744769WFH Guidelines for the Management of Hemophilia, 3rd edition.Haemophilia2020https://conductscience.org/library/papers/32744769PubMed
1911187870The German Registry of immune tolerance treatment in hemophilia--1999 update.Haematologica2000https://conductscience.org/library/papers/11187870PubMed
2018081830Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.Haemophilia2008https://conductscience.org/library/papers/18081830PubMed

See all 31 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
42148133Outcomes of low-dose immune tolerance induction with single-dose rituximab in severe hemophilia A: a single-center retrospective experience.Front Immunol2026https://conductscience.org/library/papers/42148133PubMed
42088902Emicizumab prophylaxis vs immune tolerance induction in children with severe hemophilia A and inhibitors: a retrospective comparison of bleeding control, quality of life, and cost.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/42088902PubMed
39810987Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial.Res Pract Thromb Haemost2025https://conductscience.org/library/papers/39810987PubMed
39698264Advances in Development of Drug Treatment for Hemophilia with Inhibitors.ACS Pharmacol Transl Sci2024https://conductscience.org/library/papers/39698264PubMed
38910855Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL.Pediatr Investig2024https://conductscience.org/library/papers/38910855PubMed
38185516[Chinese guidelines on the diagnosis and management of hemophilia with inhibitors (2023)].Zhonghua Xue Ye Xue Za Zhi2023https://conductscience.org/library/papers/38185516PubMed
36313984Low-dose immune tolerance induction in children with severe hemophilia A with high-titer inhibitors: Type of factor 8 mutation and outcomes.Res Pract Thromb Haemost2022https://conductscience.org/library/papers/36313984PubMed
34278191Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.Res Pract Thromb Haemost2021https://conductscience.org/library/papers/34278191PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
F82157PubTator's text mininghttps://conductscience.org/library/genes/2157NCBI Gene
VWF7450PubTator's text mininghttps://conductscience.org/library/genes/7450NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34278191

GET https://conductscience.org/api/papers/v1/34278191/references?page=2